Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 557 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gene sequencing Clear all
Completed No phase listed Observational

Molecular Determinants of Acquired Clinical Resistance to Crizotinib in Non-small Cell Lung Cancer Harboring a Translocation or Inversion Event Involving the ALK Gene Locus

NCT01300429
View directory record Official record
Conditions
Lung Cancer
Interventions
obtain tissue specimens
Genetic
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Nov 4, 2026, 4:15 AM EST
Active, not recruiting No phase listed Observational

Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment

NCT02243592
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
73
States / cities
Duarte, California • Fresno, California • Oakland, California + 58 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Nov 4, 2026, 4:15 AM EST
Recruiting Phase 4 Interventional

EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing

NCT06105801
View directory record Official record
Conditions
Lung Cancer
Interventions
Endobronchial ultrasound with transbronchial needle aspiration, Bronchoscopy, Cryobiopsy
Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Nov 4, 2026, 4:15 AM EST
Recruiting Phase 1Phase 2 Interventional

Avo In R/R And Previously Untreated MCL

NCT04855695
View directory record Official record
Conditions
Mantle Cell Lymphoma, Refractory Lymphoma
Interventions
Acalabrutinib, Venetoclax, Obinutuzumab
Drug
Lead sponsor
Austin I Kim
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Nov 4, 2026, 4:15 AM EST
Enrolling by invitation Not applicable Interventional

Treatment of Cognitive and Sensorimotor Deficits in Parkinson's Disease With High Definition Transcranial Direct Current Stimulation

NCT07534397
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder)
Interventions
transcranial direct current stimulation, Sham transcranial direct current stimulation
Device
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 4, 2026, 4:15 AM EST
Recruiting Not applicable Interventional

Connectomic Alterations Following Acute Ischemic Stroke in the MCA Territory

NCT07584681
View directory record Official record
Conditions
Ischemic Stroke
Interventions
MRI with connectomic sequencing
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 4, 2026, 4:15 AM EST
Recruiting No phase listed Observational

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

NCT05935384
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
Interventions
Guardant360
Diagnostic Test
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Skokie, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Nov 4, 2026, 4:15 AM EST
Recruiting Not applicable Interventional

Virtual Home-based Exercise Intervention (RISE) to Improve Cancer-Related Cognitive Impairment and Gut Microbiome in Adolescent and Young Adult Brain Tumor Survivors

NCT06799481
View directory record Official record
Conditions
Cancer-related Cognitive Dysfunction, Primary Brain Neoplasm
Interventions
Aerobic Exercise, Behavioral Intervention, Follow-Up, Internet-Based Intervention, Medical Device Usage and Evaluation, Questionnaire Administration, Resistance Training
Other · Behavioral · Procedure
Lead sponsor
Emory University
Other
Eligibility
15 Years to 39 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Nov 4, 2026, 4:15 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Genomic Uniformed-Screening Against Rare Disease In All Newborns

NCT05990179
View directory record Official record
Conditions
Early Onset Genetic Conditions With Near Complete Penetrance
Interventions
Genome sequencing-based newborn screening
Other
Lead sponsor
Columbia University
Other
Eligibility
1 Day to 1 Month
Enrollment
100,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Nov 4, 2026, 4:15 AM EST
Completed No phase listed Observational

Pediatric Infectious Disease Precision Medicine Using Sequencing Evaluation of CSF

NCT03796546
View directory record Official record
Conditions
Infection, Meningitis
Interventions
Not listed
Lead sponsor
IDbyDNA, Inc.
Industry
Eligibility
0 Years to 17 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Orange, California • San Diego, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Nov 4, 2026, 4:15 AM EST
Recruiting No phase listed Observational

Precision Medicine Approaches to Renal Osteodystrophy

NCT05880914
View directory record Official record
Conditions
Renal Osteodystrophy, Chronic Kidney Diseases, CKD-MBD, Bone Turnover Rate Disorder, Secondary Hyperparathyroidism
Interventions
miRNAseq analysis, Standard treatment for bone disorder
Procedure · Drug
Lead sponsor
Thomas Nickolas
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 4, 2026, 4:15 AM EST
Completed Not applicable Interventional

Flourish HEC to Prevent Recurrence of BV

NCT05386147
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
Flourish HEC Vaginal Care System (contains a class II medical device plus other unregulated components)
Device
Lead sponsor
Vaginal Biome Science
Other
Eligibility
18 Years to 52 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rosemont, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2024 · Synced Nov 4, 2026, 4:15 AM EST
Completed No phase listed Observational

Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy

NCT01953640
View directory record Official record
Conditions
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 4, 2026, 4:15 AM EST
Completed Not applicable Interventional

Diabetic Foot Ulcer (DFU) Rapid Pathogen Identification

NCT06569238
View directory record Official record
Conditions
Diabetic Foot Ulcer, Diabetes Mellitus, Wound
Interventions
Conventional bacterial culture, Rapid diagnostic group using mNGS technology
Diagnostic Test · Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Nov 4, 2026, 4:15 AM EST
Completed No phase listed Observational

Identifying Molecular Drivers of Cancer

NCT02470715
View directory record Official record
Conditions
Cancer, Tumor, Advanced Cancer
Interventions
Molecular profile
Genetic
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Nov 4, 2026, 4:15 AM EST
Completed Phase 2 Interventional Results available

Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer

NCT01487863
View directory record Official record
Conditions
Prostate Cancer Metastatic, Hormone Refractory Prostate Cancer, Castration-resistant Prostate Cancer
Interventions
sipuleucel-T, abiraterone acetate
Biological · Drug
Lead sponsor
Dendreon
Industry
Eligibility
18 Years and older · Male only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
21
States / cities
La Jolla, California • La Mesa, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Nov 4, 2026, 4:15 AM EST
Not listed No phase listed Observational

Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors

NCT02092714
View directory record Official record
Conditions
Neuroendocrine Tumor
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Nov 4, 2026, 4:15 AM EST
Terminated No phase listed Observational

Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma

NCT02549638
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Carcinoma, Squamous, Squamous Cell Carcinoma, Lung Neoplasms, Cancer of Lung, Cancer of the Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms
Interventions
DNA Extraction
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Nov 4, 2026, 4:15 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

NCT01050504
View directory record Official record
Conditions
Localized Renal Pelvis and Ureter Urothelial Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Soft Tissues, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Recurrent Bladder Carcinoma, Recurrent Prostate Carcinoma, Recurrent Renal Pelvis and Ureter Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v7, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 4, 2026, 4:15 AM EST
Terminated Not applicable Interventional Accepts healthy volunteers

Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples

NCT03020121
View directory record Official record
Conditions
Uterine Cervical Neoplasm
Interventions
Colposcopy/biopsy
Procedure
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
21 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
11
States / cities
Denver, Colorado • West Palm Beach, Florida • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Nov 4, 2026, 4:15 AM EST
Terminated No phase listed Observational

Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab

NCT04791215
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Observational
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Nov 4, 2026, 4:15 AM EST
Recruiting No phase listed Observational

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer

NCT02610413
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2100
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Nov 4, 2026, 4:15 AM EST
Recruiting Not applicable Interventional

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

NCT07067138
View directory record Official record
Conditions
Breast Cancer, Breast Carcinoma, Cancer of the Breast, Malignant Neoplasm of Breast
Interventions
Expression Networks for highLIGHting Tumor vulnerabilities (ENLIGHT), TruSight(R) Oncology 500, TruSeq Matched Tumor Normal Whole Exome Sequencing Assay
Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 4, 2026, 4:15 AM EST
Terminated Not applicable Interventional

iCare for Cancer Patients

NCT02435550
View directory record Official record
Conditions
Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Leukemia, Acute Lymphoblastic, Multiple Myeloma, Myelofibrosis
Interventions
Molecular diagnostic testing
Genetic
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Nov 4, 2026, 4:15 AM EST